ODACon™ Virtual Conference
The Oncology Data Advisor Supportive Care Summit brings together world-renowned faculty to discuss and debate best practices in oncology supportive care. This year’s event will provide expert perspectives and guidance on evidence-based supportive care for patients receiving novel breast cancer therapies. Please join us for an exciting and interactive robust online professional development experience. Register now!
Presented by Dr. Shawn Kwatra, Director, John Hopkins Itch Center, Associate Professor of Dermatology, John Hopkins University School of Medicine and Dr. Linda Stein Gold, Director of Dermatology Clinical Research, Division Head of Dermatology, Henry Ford Health System, this expert led discussion will direct thoughtful consideration of the health care disparities faced by Black patients with AD, best practices in diagnosis and assessment, and the applicability of novel therapeutic approaches for moderate-to-severe disease.
Presented by Amir Fathi, MD, Associate Professor of Medicine at Harvard Medical School, this activity will highlight individualized treatment selection for patients with acute lymphoblastic leukemia (ALL), as well as recent efficacy and safety data for novel therapeutic strategies. Start the activity now.
This in-depth discussion, presented by Louis Diehl, MD, Professor of Medicine at Duke University Medical School, will feature strategies for incorporating predictive and prognostic markers, recent efficacy and safety data, and adverse event management strategies into treatment selection for patients with Hodgkin lymphoma (HL). Start the activity now.
Discover insights on predictive and prognostic markers, emerging efficacy and safety data, strategies to optimize tolerability for patients receiving novel therapies for mantle cell lymphoma (MCL), and more in this case-based activity presented by John Leonard, MD, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine. Start the activity now.
This activity, presented by Mikkael Sekeres, MD, Chief of the Division of Hematology at the University of Miami Health System, will focus on predictive and prognostic markers for myelodysplastic syndromes (MDS), emerging data on novel therapies, and strategies to optimize safety and tolerability for patients with this disease. Start the activity now.
In this case-based discussion, Morie Gertz, MD, Chair of General Internal Medicine at the Mayo Clinic in Minnesota, will discuss how to use predictive and prognostic markers to select treatment for patients with Waldenstrom macroglobulinemia (WM) and how to appraise emerging clinical trial data and adverse event management strategies for novel treatments. Start the activity now.
Gain expert insight on new data and emerging strategies for patients with migraine headaches including prevention, treatment, and strategies for management related to adverse events and supportive care. Presented by Jessica Ailani, MD, Director, MedStar Georgetown Headache Center, MedStar Georgetown Univeristy Hospital, and Calli Cook, DNP, APRN, FNP-C, FAANP, Clinical Assistant Professor, Nell Hodgson Woodruff School of Nursing, Emory University. Start the activity now!
Explore best practices in the management of tumor lysis syndrome associated with emerging cancer therapies. This activity, presented by Matthew S. Davids, MD, MMSc, Director of Clinical Research at Dana-Farber Cancer Institute, and Amy Goodrich, RN, BSN, MSN, CRNP-AC, Nurse Practitioner at Johns Hopkins Kimmel Cancer Center, will review plans to optimize prevention, recognition, and treatment, as well as discuss emerging therapies and monitoring strategies for patient care. Start the activity now!